Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H20N2O2S.ClH |
Molecular Weight | 352.879 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)C1=C(N)SC2=C1CCN(CC3=CC=CC=C3)C2
InChI
InChIKey=LMAQHEGFQZGATE-UHFFFAOYSA-N
InChI=1S/C17H20N2O2S.ClH/c1-2-21-17(20)15-13-8-9-19(11-14(13)22-16(15)18)10-12-6-4-3-5-7-12;/h3-7H,2,8-11,18H2,1H3;1H
Molecular Formula | C17H20N2O2S |
Molecular Weight | 316.418 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.obatinfo.com/2010/01/nonflamin.htmlCurator's Comment: description was created based on several sources, including:
http://www.obatapasaja.com/2015/05/komposisi-dosis-dan-harga-nonflamin.html
http://www.ncbi.nlm.nih.gov/pubmed/702946
Sources: http://www.obatinfo.com/2010/01/nonflamin.html
Curator's Comment: description was created based on several sources, including:
http://www.obatapasaja.com/2015/05/komposisi-dosis-dan-harga-nonflamin.html
http://www.ncbi.nlm.nih.gov/pubmed/702946
Tinoridine is a non-steroidal anti-inflammatory and analgesic agent. This agent has been proved pharmacologically to show antiedematous and analgesic actions. The mechanism of the anti-inflammatory action of Tinoridine is attributed to its biomembrane stabilizing action particularly on the lysosomes which are related to cell or tissue damage at the time of inflammation through the release of hydrolytic enzymes. Tinoridine may produce gastrointestinal disorders (nausea, loss of appetite, diarrhea, and constipation), vertigo drowsiness, dry mouth and itching.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0034440 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Nonflamin Approved UseTinoridine is indicated as anti-inflammatory agent after surgery injuries or injury in urology. |
|||
Primary | Nonflamin Approved UseTinoridine is used to treat pharyngitis, laryngitis, tonsillitis. |
|||
Primary | Nonflamin Approved UseFor analgesic purpose, Tinoridine is used to treat back pain. |
|||
Primary | Nonflamin Approved UseFor analgesic purpose, Tinoridine is used to treat lumbago. |
|||
Primary | Nonflamin Approved UseTinoridine is indicated to treat pain in chronic rheumatic diseases. |
Sample Use Guides
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/702946
Curator's Comment: Tinoridine, at concentrations from 5 microM up to 100 microM, produced a concentration-dependent inhibition on the simultaneous increases in lipid peroxide formation and renin release induced by 50 microM ascorbic acid in the renin granule fraction.
http://www.ncbi.nlm.nih.gov/pubmed/3906080
30 uM of Tinoridine HCl hydrochloride inhibited the Phospholipase C-induced lysosomal enzyme release from rat liver lysosomes.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:47:55 GMT 2023
by
admin
on
Fri Dec 15 18:47:55 GMT 2023
|
Record UNII |
05IIB89IVA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60947048
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
100000084609
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
246-103-6
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
ALTERNATIVE | |||
|
24237-55-6
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
DBSALT002331
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
m1263
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB04880MIG
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL592943
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
05IIB89IVA
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
247-342-9
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
C100290
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
25913-34-2
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY | |||
|
134896
Created by
admin on Fri Dec 15 18:47:55 GMT 2023 , Edited by admin on Fri Dec 15 18:47:55 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |